Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review
Background: Prostate-specific membrane antigen (PSMA) is not sufficiently overexpressed in a small proportion of prostate cancer (PCa) patients, who require other strategies for imaging and/or treatment. We reviewed potential targets other than PSMA for PCa theranostics in nuclear medicine that have...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8988e2088a0847deb5a3abe8920cc3f5 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:8988e2088a0847deb5a3abe8920cc3f5 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:8988e2088a0847deb5a3abe8920cc3f52021-11-11T17:33:23ZPotential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review10.3390/jcm102149092077-0383https://doaj.org/article/8988e2088a0847deb5a3abe8920cc3f52021-10-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/4909https://doaj.org/toc/2077-0383Background: Prostate-specific membrane antigen (PSMA) is not sufficiently overexpressed in a small proportion of prostate cancer (PCa) patients, who require other strategies for imaging and/or treatment. We reviewed potential targets other than PSMA for PCa theranostics in nuclear medicine that have already been tested in humans. Methods: We performed a systematic web search in the PubMed and Cochrane databases, with no time restrictions by pooling terms (“prostate cancer”, “prostatic neoplasms”) and (“radioligand”, “radiotracer”). Included articles were clinical studies. The results were synthetized by the target type. Results: We included 38 studies on six different targets: gastrin-releasing peptide receptors (GRPRs) (<i>n</i> = 23), androgen receptor (<i>n</i> = 11), somatostatin receptors (<i>n</i> = 6), urokinase plasminogen activator surface receptor (<i>n</i> = 4), fibroblast activation protein (<i>n</i> = 2 studies) and integrin receptors (<i>n</i> = 1). GRPRs, the most studied target, has a lower expression in high-grade PCa, CRPC and bone metastases. Its use might be of higher interest in treating earlier stages of PCa or low-grade PCa. Radiolabeled fibroblast activation protein inhibitors were the most recent and promising molecules, but specific studies reporting their interest in PCa are needed. Conclusion: Theranostics in nuclear medicine will continue to develop in the future, especially for PCa patients. Targets other than PSMA exist and deserve to be promoted.Mathieu GauthéPaul SargosEric BarretGaëlle Fromont-HankardJean-Baptiste BeauvalLaurent BrureauGilles CréhangeRaphaële Renard-PennaCharles DarianeGaëlle FiardRomain MathieuGuilhem RoubaudAlain RuffionMorgan RouprêtGuillaume Ploussardon behalf of the CC-AFU MDPI AGarticlenuclear medicinetherapeuticsmolecular imagingMedicineRENJournal of Clinical Medicine, Vol 10, Iss 4909, p 4909 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
nuclear medicine therapeutics molecular imaging Medicine R |
| spellingShingle |
nuclear medicine therapeutics molecular imaging Medicine R Mathieu Gauthé Paul Sargos Eric Barret Gaëlle Fromont-Hankard Jean-Baptiste Beauval Laurent Brureau Gilles Créhange Raphaële Renard-Penna Charles Dariane Gaëlle Fiard Romain Mathieu Guilhem Roubaud Alain Ruffion Morgan Rouprêt Guillaume Ploussard on behalf of the CC-AFU Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review |
| description |
Background: Prostate-specific membrane antigen (PSMA) is not sufficiently overexpressed in a small proportion of prostate cancer (PCa) patients, who require other strategies for imaging and/or treatment. We reviewed potential targets other than PSMA for PCa theranostics in nuclear medicine that have already been tested in humans. Methods: We performed a systematic web search in the PubMed and Cochrane databases, with no time restrictions by pooling terms (“prostate cancer”, “prostatic neoplasms”) and (“radioligand”, “radiotracer”). Included articles were clinical studies. The results were synthetized by the target type. Results: We included 38 studies on six different targets: gastrin-releasing peptide receptors (GRPRs) (<i>n</i> = 23), androgen receptor (<i>n</i> = 11), somatostatin receptors (<i>n</i> = 6), urokinase plasminogen activator surface receptor (<i>n</i> = 4), fibroblast activation protein (<i>n</i> = 2 studies) and integrin receptors (<i>n</i> = 1). GRPRs, the most studied target, has a lower expression in high-grade PCa, CRPC and bone metastases. Its use might be of higher interest in treating earlier stages of PCa or low-grade PCa. Radiolabeled fibroblast activation protein inhibitors were the most recent and promising molecules, but specific studies reporting their interest in PCa are needed. Conclusion: Theranostics in nuclear medicine will continue to develop in the future, especially for PCa patients. Targets other than PSMA exist and deserve to be promoted. |
| format |
article |
| author |
Mathieu Gauthé Paul Sargos Eric Barret Gaëlle Fromont-Hankard Jean-Baptiste Beauval Laurent Brureau Gilles Créhange Raphaële Renard-Penna Charles Dariane Gaëlle Fiard Romain Mathieu Guilhem Roubaud Alain Ruffion Morgan Rouprêt Guillaume Ploussard on behalf of the CC-AFU |
| author_facet |
Mathieu Gauthé Paul Sargos Eric Barret Gaëlle Fromont-Hankard Jean-Baptiste Beauval Laurent Brureau Gilles Créhange Raphaële Renard-Penna Charles Dariane Gaëlle Fiard Romain Mathieu Guilhem Roubaud Alain Ruffion Morgan Rouprêt Guillaume Ploussard on behalf of the CC-AFU |
| author_sort |
Mathieu Gauthé |
| title |
Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review |
| title_short |
Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review |
| title_full |
Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review |
| title_fullStr |
Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review |
| title_full_unstemmed |
Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review |
| title_sort |
potential targets other than psma for prostate cancer theranostics: a systematic review |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/8988e2088a0847deb5a3abe8920cc3f5 |
| work_keys_str_mv |
AT mathieugauthe potentialtargetsotherthanpsmaforprostatecancertheranosticsasystematicreview AT paulsargos potentialtargetsotherthanpsmaforprostatecancertheranosticsasystematicreview AT ericbarret potentialtargetsotherthanpsmaforprostatecancertheranosticsasystematicreview AT gaellefromonthankard potentialtargetsotherthanpsmaforprostatecancertheranosticsasystematicreview AT jeanbaptistebeauval potentialtargetsotherthanpsmaforprostatecancertheranosticsasystematicreview AT laurentbrureau potentialtargetsotherthanpsmaforprostatecancertheranosticsasystematicreview AT gillescrehange potentialtargetsotherthanpsmaforprostatecancertheranosticsasystematicreview AT raphaelerenardpenna potentialtargetsotherthanpsmaforprostatecancertheranosticsasystematicreview AT charlesdariane potentialtargetsotherthanpsmaforprostatecancertheranosticsasystematicreview AT gaellefiard potentialtargetsotherthanpsmaforprostatecancertheranosticsasystematicreview AT romainmathieu potentialtargetsotherthanpsmaforprostatecancertheranosticsasystematicreview AT guilhemroubaud potentialtargetsotherthanpsmaforprostatecancertheranosticsasystematicreview AT alainruffion potentialtargetsotherthanpsmaforprostatecancertheranosticsasystematicreview AT morganroupret potentialtargetsotherthanpsmaforprostatecancertheranosticsasystematicreview AT guillaumeploussard potentialtargetsotherthanpsmaforprostatecancertheranosticsasystematicreview AT onbehalfoftheccafu potentialtargetsotherthanpsmaforprostatecancertheranosticsasystematicreview |
| _version_ |
1718432074415734784 |